Education
About Us
Working with TipRanks
Follow Us
Hangzhou Tigermed Consulting Co., Ltd. Class H (HK:3347)
:3347
3347 Stock Chart & Stats
HK$39.70
HK$0.35(1.23%)
At close: 4:00 PM EST
HK$39.70
HK$0.35(1.23%)
Day’s Range― - ―
52-Week RangeHK$22.30 - HK$60.60
Previous CloseN/A
Volume678.40K
Average Volume (3M)2.64M
Market Cap
HK$42.91B
Enterprise ValueHK$36.84B
Total Cash (Recent Filing)HK$1.82B
Total Debt (Recent Filing)HK$2.38B
Price to Earnings (P/E)50.8
Beta1.81
Next Earnings
Mar 30, 2026EPS Estimate
0.43Next Dividend Ex-DateN/A
Dividend Yield0.82%
Share Statistics
EPS (TTM)0.81
Shares Outstanding123,124,800
10 Day Avg. Volume1,735,173
30 Day Avg. Volume2,642,557
Financial Highlights & Ratios
PEG Ratio-0.77
Price to Book (P/B)1.21
Price to Sales (P/S)3.79
P/FCF Ratio33.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$52.91Price Target Upside33.27% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Hangzhou Tigermed Consulting Co., Ltd. Class H News
3347 FAQ
What was Hangzhou Tigermed Consulting Co., Ltd. Class H’s price range in the past 12 months?
Hangzhou Tigermed Consulting Co., Ltd. Class H lowest stock price was HK$22.30 and its highest was HK$60.60 in the past 12 months.
What is Hangzhou Tigermed Consulting Co., Ltd. Class H’s market cap?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s market cap is HK$42.91B.
When is Hangzhou Tigermed Consulting Co., Ltd. Class H’s upcoming earnings report date?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s upcoming earnings report date is Mar 30, 2026 which is in 104 days.
How were Hangzhou Tigermed Consulting Co., Ltd. Class H’s earnings last quarter?
Hangzhou Tigermed Consulting Co., Ltd. Class H released its earnings results on Oct 28, 2025. The company reported HK$0.81 earnings per share for the quarter, beating the consensus estimate of HK$0.345 by HK$0.465.
Is Hangzhou Tigermed Consulting Co., Ltd. Class H overvalued?
According to Wall Street analysts Hangzhou Tigermed Consulting Co., Ltd. Class H’s price is currently Undervalued.
Does Hangzhou Tigermed Consulting Co., Ltd. Class H pay dividends?
Hangzhou Tigermed Consulting Co., Ltd. Class H pays a Annually dividend of HK$0.325 which represents an annual dividend yield of 0.82%. See more information on Hangzhou Tigermed Consulting Co., Ltd. Class H dividends here
What is Hangzhou Tigermed Consulting Co., Ltd. Class H’s EPS estimate?
Hangzhou Tigermed Consulting Co., Ltd. Class H’s EPS estimate is 0.43.
How many shares outstanding does Hangzhou Tigermed Consulting Co., Ltd. Class H have?
Hangzhou Tigermed Consulting Co., Ltd. Class H has 123,124,800 shares outstanding.
What happened to Hangzhou Tigermed Consulting Co., Ltd. Class H’s price movement after its last earnings report?
Hangzhou Tigermed Consulting Co., Ltd. Class H reported an EPS of HK$0.81 in its last earnings report, beating expectations of HK$0.345. Following the earnings report the stock price went down -0.324%.
Which hedge fund is a major shareholder of Hangzhou Tigermed Consulting Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:3347
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Hangzhou Tigermed Consulting Co., Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
2.72%
Trailing 12-Months
Asset Growth
-13.28%
Trailing 12-Months
Company Description
Hangzhou Tigermed Consulting Co., Ltd. Class H
Hangzhou Tigermed Consulting Co., Ltd. is a leading clinical research organization (CRO) based in China, specializing in providing comprehensive services for the pharmaceutical, biotechnology, and medical device industries. The company operates in various sectors including clinical trial management, regulatory affairs, and data management, offering solutions that streamline the research and development process for its clients. Tigermed's core services encompass clinical trial design, site management, patient recruitment, and monitoring, as well as consulting services that aid in navigating complex regulatory environments.
3347 Stock 12 Month Forecast
Average Price Target
HK$52.91
▲(33.27% Upside)
Technical Analysis
Pharmaron Beijing Co., Ltd. Class H
―
Shanghai Conant Optical Co. Ltd. Class H
―
Giant Biogene Holding Co. Ltd.
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―
Options Prices
Currently, No data available
---